How much profit has TBG Diagnostics made this year?
TBG Diagnostics has made 0 AUD this year.
TBG Diagnostics Net Income 2024
TBG Diagnostics Net Income
0 AUD
Ticker
TDL.AX
ISIN
AU000000TDL4
WKN
A2AD8F
In 2024, TBG Diagnostics's profit amounted to 0 AUD, a 0% increase from the 0 AUD profit recorded in the previous year.
The TBG Diagnostics Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022e | - |
| 2021e | - |
| 2020 | -3,548.98 |
| 2019 | 764.94 |
| 2018 | -4,149.79 |
| 2017 | -6,540.39 |
| 2016 | -2,621.09 |
| 2015 | -1,859.56 |
| 2014 | -1,810 |
| 2013 | -2,090 |
| 2012 | -3,440 |
| 2011 | -6,100 |
| 2010 | -15,840 |
| 2009 | -5,470 |
| 2008 | -26,150 |
| 2007 | -22,450 |
| 2006 | -7,610 |
| 2005 | -5,940 |
| 2004 | -4,780 |
| 2003 | -7,580 |
| 2002 | -6,160 |
| 2001 | -1,150 |
TBG Diagnostics Revenue, EBIT, Net Income AU000000TDL4 · A2AD8F
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into TBG Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TBG Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TBG Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of TBG Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into TBG Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing TBG Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TBG Diagnostics’s growth potential.
TBG Diagnostics Revenue, EBIT and net profit per share
| Date | TBG Diagnostics Revenue | TBG Diagnostics EBIT | TBG Diagnostics Net Income |
|---|---|---|---|
| 2025e | 213 M undefined | 0 undefined | 0 undefined |
| 2024e | 182.76 M undefined | 0 undefined | 0 undefined |
| 2023e | 156.76 M undefined | 0 undefined | 0 undefined |
| 2022e | 128.99 M undefined | 0 undefined | 0 undefined |
| 2021e | 112.7 M undefined | 0 undefined | 0 undefined |
| 2020 | 4.63 M undefined | -3.04 M undefined | -3.55 M undefined |
| 2019 | 3.44 M undefined | -2.05 M undefined | 764,940 undefined |
| 2018 | 3.24 M undefined | -2.64 M undefined | -4.15 M undefined |
| 2017 | 4.6 M undefined | -1.71 M undefined | -6.54 M undefined |
| 2016 | 1.39 M undefined | -2.81 M undefined | -2.62 M undefined |
| 2015 | 806,590 undefined | -1.86 M undefined | -1.86 M undefined |
| 2014 | 5.75 M undefined | -1.81 M undefined | -1.81 M undefined |
| 2013 | 3.51 M undefined | -2.81 M undefined | -2.09 M undefined |
| 2012 | 2.89 M undefined | -3.44 M undefined | -3.44 M undefined |
| 2011 | 3.67 M undefined | -6.05 M undefined | -6.1 M undefined |
| 2010 | 2.71 M undefined | -11.4 M undefined | -15.84 M undefined |
| 2009 | 4.94 M undefined | -12.29 M undefined | -5.47 M undefined |
| 2008 | 6.48 M undefined | -25.88 M undefined | -26.15 M undefined |
| 2007 | 3.78 M undefined | -20.66 M undefined | -22.45 M undefined |
| 2006 | 2.82 M undefined | -6.96 M undefined | -7.61 M undefined |
| 2005 | 3.11 M undefined | -5.92 M undefined | -5.94 M undefined |
| 2004 | 6.19 M undefined | -4.46 M undefined | -4.78 M undefined |
| 2003 | 8.16 M undefined | -3.75 M undefined | -7.58 M undefined |
| 2002 | 5.66 M undefined | -4.86 M undefined | -6.16 M undefined |
| 2001 | 3.55 M undefined | -6.32 M undefined | -1.15 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2001 | 3.55 M AUD | -6.32 M AUD | -1.15 M AUD |
| 2002 | 5.66 M AUD | -4.86 M AUD | -6.16 M AUD |
| 2003 | 8.16 M AUD | -3.75 M AUD | -7.58 M AUD |
| 2004 | 6.19 M AUD | -4.46 M AUD | -4.78 M AUD |
| 2005 | 3.11 M AUD | -5.92 M AUD | -5.94 M AUD |
| 2006 | 2.82 M AUD | -6.96 M AUD | -7.61 M AUD |
| 2007 | 3.78 M AUD | -20.66 M AUD | -22.45 M AUD |
| 2008 | 6.48 M AUD | -25.88 M AUD | -26.15 M AUD |
| 2009 | 4.94 M AUD | -12.29 M AUD | -5.47 M AUD |
| 2010 | 2.71 M AUD | -11.4 M AUD | -15.84 M AUD |
| 2011 | 3.67 M AUD | -6.05 M AUD | -6.1 M AUD |
| 2012 | 2.89 M AUD | -3.44 M AUD | -3.44 M AUD |
| 2013 | 3.51 M AUD | -2.81 M AUD | -2.09 M AUD |
| 2014 | 5.75 M AUD | -1.81 M AUD | -1.81 M AUD |
| 2015 | 806,590 AUD | -1.86 M AUD | -1.86 M AUD |
| 2016 | 1.39 M AUD | -2.81 M AUD | -2.62 M AUD |
| 2017 | 4.6 M AUD | -1.71 M AUD | -6.54 M AUD |
| 2018 | 3.24 M AUD | -2.64 M AUD | -4.15 M AUD |
| 2019 | 3.44 M AUD | -2.05 M AUD | 764,940 AUD |
| 2020 | 4.63 M AUD | -3.04 M AUD | -3.55 M AUD |
| 2021e | 112.7 M AUD | 0 AUD | 0 AUD |
| 2022e | 128.99 M AUD | 0 AUD | 0 AUD |
| 2023e | 156.76 M AUD | 0 AUD | 0 AUD |
| 2024e | 182.76 M AUD | 0 AUD | 0 AUD |
| 2025e | 213 M AUD | 0 AUD | 0 AUD |
TBG Diagnostics stock margins AU000000TDL4 · A2AD8F
The TBG Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TBG Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TBG Diagnostics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the TBG Diagnostics's sales revenue. A higher gross margin percentage indicates that the TBG Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the TBG Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the TBG Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TBG Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TBG Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TBG Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
TBG Diagnostics Margin History
| TBG Diagnostics Gross margin | TBG Diagnostics Profit margin | TBG Diagnostics EBIT margin | TBG Diagnostics Profit margin |
|---|---|---|---|
| 2025e | 57.95 % | 0 % | 0 % |
| 2024e | 57.95 % | 0 % | 0 % |
| 2023e | 57.95 % | 0 % | 0 % |
| 2022e | 57.95 % | 0 % | 0 % |
| 2021e | 57.95 % | 0 % | 0 % |
| 2020 | 57.95 % | -65.6 % | -76.57 % |
| 2019 | 76.11 % | -59.51 % | 22.21 % |
| 2018 | 88.83 % | -81.65 % | -128.17 % |
| 2017 | 83.17 % | -37.23 % | -142.25 % |
| 2016 | 70.69 % | -201.63 % | -188.36 % |
| 2015 | 67.81 % | -230.55 % | -230.55 % |
| 2014 | 54.96 % | -31.48 % | -31.48 % |
| 2013 | 57.95 % | -80.06 % | -59.54 % |
| 2012 | 7.61 % | -119.03 % | -119.03 % |
| 2011 | 31.61 % | -164.85 % | -166.21 % |
| 2010 | 25.46 % | -420.66 % | -584.5 % |
| 2009 | 65.99 % | -248.79 % | -110.73 % |
| 2008 | 58.02 % | -399.38 % | -403.55 % |
| 2007 | 37.3 % | -546.56 % | -593.92 % |
| 2006 | 26.24 % | -246.81 % | -269.86 % |
| 2005 | 83.6 % | -190.35 % | -191 % |
| 2004 | 72.21 % | -72.05 % | -77.22 % |
| 2003 | 74.88 % | -45.96 % | -92.89 % |
| 2002 | 61.84 % | -85.87 % | -108.83 % |
| 2001 | 59.15 % | -178.03 % | -32.39 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2001 | 59.15 % | -178.03 % | -32.39 % |
| 2002 | 61.84 % | -85.87 % | -108.83 % |
| 2003 | 74.88 % | -45.96 % | -92.89 % |
| 2004 | 72.21 % | -72.05 % | -77.22 % |
| 2005 | 83.6 % | -190.35 % | -191 % |
| 2006 | 26.24 % | -246.81 % | -269.86 % |
| 2007 | 37.3 % | -546.56 % | -593.92 % |
| 2008 | 58.02 % | -399.38 % | -403.55 % |
| 2009 | 65.99 % | -248.79 % | -110.73 % |
| 2010 | 25.46 % | -420.66 % | -584.5 % |
| 2011 | 31.61 % | -164.85 % | -166.21 % |
| 2012 | 7.61 % | -119.03 % | -119.03 % |
| 2013 | 57.95 % | -80.06 % | -59.54 % |
| 2014 | 54.96 % | -31.48 % | -31.48 % |
| 2015 | 67.81 % | -230.55 % | -230.55 % |
| 2016 | 70.69 % | -201.63 % | -188.36 % |
| 2017 | 83.17 % | -37.23 % | -142.25 % |
| 2018 | 88.83 % | -81.65 % | -128.17 % |
| 2019 | 76.11 % | -59.51 % | 22.21 % |
| 2020 | 57.95 % | -65.6 % | -76.57 % |
| 2021e | 57.95 % | 0 % | 0 % |
| 2022e | 57.95 % | 0 % | 0 % |
| 2023e | 57.95 % | 0 % | 0 % |
| 2024e | 57.95 % | 0 % | 0 % |
| 2025e | 57.95 % | 0 % | 0 % |
TBG Diagnostics Aktienanalyse
What does TBG Diagnostics do?
TBG Diagnostics Ltd is an Australian company specializing in the manufacturing and marketing of in vitro diagnostic products. The company was originally founded in 2009 under the name TBG Biotechnology Pty Ltd and later became a corporation. The company's business model is to provide fast and reliable diagnostic solutions for various disease conditions. The company operates in various areas, including infectious diseases, diarrheal diseases, tumor diagnostics, cardiovascular diseases, and oncology. In the infectious diseases field, for example, TBG Diagnostics offers test kits for the diagnosis of HIV, hepatitis, dengue fever, and other infectious diseases. The test kits consist of immunological rapid tests that typically provide results within 15-20 minutes, allowing doctors to quickly make a diagnosis and initiate appropriate therapy. In the diarrheal diseases field, the company has developed a special test kit that allows for the detection of rotaviruses. Rotavirus infections are one of the most common causes of severe diarrhea in infants and can lead to serious complications if left untreated. TBG Diagnostics' tumor diagnostics division offers specialized test kits for the diagnosis of prostate cancer, breast cancer, and colorectal cancer. The test kits are based on the measurement of tumor markers in the blood and are a fast and non-invasive method for early cancer detection. The company's cardiovascular division offers test kits for the diagnosis of thyroid hormones and troponin. Troponin is a protein complex that is released into the blood in increased amounts when there is damage to the heart muscle and can be an indication of a heart attack. In collaboration with partners, TBG Diagnostics also develops innovative solutions for oncology. One example is a special test kit that enables personalized medicine for patients with advanced bladder cancer. The test kit analyzes the DNA of tumor cells and allows doctors to find individually tailored therapies for the patient. TBG Diagnostics is a successful company that has experienced steady growth in recent years. The company is listed on the Australian stock exchange and has a strong international distribution network, enabling it to distribute its products worldwide. Overall, TBG Diagnostics is a company specializing in the development and manufacturing of innovative diagnostic products. By focusing on various areas and collaborating with partners, the company can quickly respond to changing requirements in healthcare and offer customized solutions to its customers. TBG Diagnostics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding TBG Diagnostics's Profit Margins
The profit margins of TBG Diagnostics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of TBG Diagnostics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating TBG Diagnostics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
TBG Diagnostics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When TBG Diagnostics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about TBG Diagnostics stock
How has the profit developed compared to last year?
The profit has increased by 0% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does TBG Diagnostics publish its earnings?
TBG Diagnostics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of TBG Diagnostics?
The profits of TBG Diagnostics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of TBG Diagnostics?
You can learn more about the earnings of TBG Diagnostics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does TBG Diagnostics pay?
Over the past 12 months, TBG Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TBG Diagnostics is expected to pay a dividend of 0 AUD.
What is the dividend yield of TBG Diagnostics?
The current dividend yield of TBG Diagnostics is .
When does TBG Diagnostics pay dividends?
TBG Diagnostics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of TBG Diagnostics?
TBG Diagnostics paid dividends every year for the past 0 years.
What is the dividend of TBG Diagnostics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is TBG Diagnostics located?
TBG Diagnostics is assigned to the 'Health' sector.
Wann musste ich die Aktien von TBG Diagnostics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of TBG Diagnostics from 10/4/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did TBG Diagnostics pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of TBG Diagnostics in the year 2023?
In the year 2023, TBG Diagnostics distributed 0 AUD as dividends.
In which currency does TBG Diagnostics pay out the dividend?
The dividends of TBG Diagnostics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von TBG Diagnostics
Our stock analysis for TBG Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TBG Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- TBG Diagnostics Revenue
- TBG Diagnostics Net Income
- TBG Diagnostics P/E
- TBG Diagnostics P/S
- TBG Diagnostics EBIT
- TBG Diagnostics Dividend
- TBG Diagnostics Stocks
- TBG Diagnostics Market capitalization
- TBG Diagnostics Debt
- TBG Diagnostics Liabilities
- TBG Diagnostics Equity
- TBG Diagnostics AAQS
- TBG Diagnostics Employees
- TBG Diagnostics ROE
- TBG Diagnostics ROA
- TBG Diagnostics ROCE
